Future quarters will compensate for wanting mpox sales, says Bavarian Nordic CFO
Sales of Bavarian Nordic’s mpox vaccine aren’t as good considering where they need to be at year end. ”Other quarters must be stronger,” says CFO Henrik Juuel.
by marketwire, translated by daniel pedersen
Danish vaccine maker Bavarian Nordic must ramp up sales of its vaccine against smallpox and mpox in coming quarters if its own expectations for the year are to be met.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
